Compliance review: Sun Pharma’s Halol plant gets 8 USFDA observations; company vows remedial steps after inspection – Times of India
Sun Pharmaceutical Industries Ltd on Saturday said the US Food and Drug Administration (USFDA) has issued a Form 483 with eight observations following an inspection of its Halol manufacturing facility in Gujarat.The inspection, which focused on Good Manufacturing Practices (GMP), was conducted between June 2 and June 13, 2025, the company said in a regulatory…
